NCT: NCT04313127
“A randomized, double-blind, placebo parallel-controlled phase I/II clinical trials for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells)” have established a positive antibody response or the seroconversion along with CD4+ and CD8+ T cell response. | 2 | Inactivated viral vaccine/ Inactivated/ -/ ( ) | Wuhan Institute of Biological Products/Sinopharm | Phase 1/2: ChiCTR2000031809 | Animal trials suggest that the vaccine protects the model animals without Antibody dependent enhancement (ADE). |
3 | Lentiviral based Minigene dendritic cell (DC) and T cell vaccine (LV-SMENP-DC)/ - / ( ; ) | Shenzhen Geno-Immune Medical Institute | Phase 1: NCT04276896 | LV-SMENP-DC vaccine is designed by altering DC with lentivirus vectors to express the “SARS-CoV-2 SMENP minigene and immune modulatory genes”. LV-DC that presents SARS-CoV-2 specific antigens will activate the CTLs |
4 | The COVID-19/aAPCs : Pathogen-specific artificial antigen presenting cells (aAPC)/-/ ( ) | Shenzhen Geno-Immune Medical Institute | Phase 1 NCT04299724 | Constructed through modifications of lentivirus by including immune modulatory genes along with viral minigenes, and antigens are presented on artificial antigen presenting cells (aAPCs). |
5 | ChAdOx1/ Non-replicating viral vector/ MERS, influenza, TB, Chikungunya, Zika, MenB, plague/ ( ; ) | University of Oxford/AstraZeneca | Phase 3: ISRCTN89951424 Phase2b/3: NCT04324606 | A phase I/II single-blinded, randomized, placebo controlled, multi-center study was conducted to determine efficacy, safety, and immunogenicity of this vaccine in UK with healthy adult volunteers aged 18-55 years. The post-vaccination follow-ups are ongoing for the 1000 volunteers. Meanwhile taking the vaccine to the higher levels of clinical trials. |
6 | Inactivated (formaldehyde inactivated + alum)/ SARS/ ( ; ) | Sinovac | Phase I/II: NCT04352608 NCT04282574 | The double-blind, placebo-controlled phase I trials showed the nAb seroconversion rate to be as high as 90% in 143 adults within 14 days of immunization. |
7 | Adeno-based Gam-COVID-Vac/ Non-replicating viral vector/-/ ( ; ) | Gamaleya Research Institute | Phase I: NCT04436471 NCT04437875 | Two types of the vaccines— fluid based and powder based for infusions — will be tried on two batches of volunteers, 38 individuals each. The members will be isolated in two Moscow medical clinics. |
8 | Ad26 (alone or with Modified Vaccinia Virus Ankara {MVA} boost) Non-replicating viral vaccine/ Ebola, HIV, RSV/ ( ; ) | Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center | Pre-Clinical (Phase 1 in September 2020) | To accelerate the development of the vaccine the company will use the AdVac® and PER.C6® technologies. |
9 | Influenza vector expressing RBD: DelNS1-SARS-CoV2-RBD/ Replicating viral vector (LAV)/ MERS/ ( ; ) | University of Hong Kong | Pre-Clinical | “It is attenuated by the deletion of a key virulent element and the immune antagonist, NS1, which is potentially more immunogenic than the wild-type influenza virus.” |
10 | CoroFlu, self-limiting influenza virus (M2SR) Non-replicating Viral Vector/ ( ; ) | University of Wisconsin-Madison / FluGen/ Bharat Biotech | Pre-Clinical | The M2SR is self-limiting because it does not undergo viral replication because of the absence of M2 gene. It will be administered via the nasal route. |
11 | Replicating viral vector/ measles vector/ West Nile, CHIKV, Ebola, Lassa, Zika, MERS/ ( ; ) | The Institut Pasteur | Pre-Clinical | The proprietary measles vector (MV) technology is chosen to develop the vaccine against SARS-CoV-2 which was used in the MV-SARS-CoV vaccine candidate. |
12 | Oral COVID-19 Vaccine/ Recombinant adenovirus type 5 vector/ CHIKV, LASV, NORV, EBOV, RVF, HBV, VEE / ( ) | Vaxart | Pre-Clinical | It will be an oral vaccine that aims to induce the mucosal immune response. |
DNA vaccines |
1 | DNA Plasmid Vaccine (INO-4800)/ Lassavirus, Nipah virus, HPV, HIV, Filovirus/ ( ; ) | Inovio Pharmaceuticals | Phase 1 NCT04336410 | Pre-clinical trials reveal induction of the antigen-specific T cell responses, and functional nAb, thus creating an obstacle for the S protein to bind to the hACE2 receptor. Phase I clinical trials will evaluate the safety, immunogenicity, and tolerability of the vaccine. |
2 | Electroporated linear DNA vaccine/ ( ) | LineaRx | Takis Biotech | Pre-Clinical | There are 4 candidates of linear DNA vaccine based upon S proteins and some selected epitopes. |
3 | Electroporated DNA vaccine/ ( ; ) | ZydusCadila | Pre-Clinical | - |
4 | DNA vaccine/ ( ) | Karolinska Institute / Cobra Biologics (OPENCORONA Project) | Pre-Clinical | A DNA vaccine, which will be administered via intramuscular injections. It will then form the viral antigens to induce the immune response. |
5 | DNA Vaccine (GX-19)/ ( ) | Genexine Consortium | Pre-Clinical | Expected to soon enter the clinical trials with Kalbe Farma. |
RNA Vaccines |
1 | LNP- Encapsulated mRNA (mRNA-1273)/ Multiple Candidates/ ( ; ) | Moderna/NIAID | Phase 2: NCT04405076 Phase 1 NCT04283461 | In Phase 1 Trials, the seroconversion resulted in the nAb levels either close to or higher than the convalescent sera. The vaccine was generally safe and well tolerated. |
2 | CureVac mRNA/ RABV, LASV, YFV, MERS, InfA, ZIKV, DengV, NIPV/ ( ; ) | CureVac | Phase 1 | mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases is used. |
3 | LNP-nCoVsaRNA/ RNA/ EBOV, LASV, YFV, MERS, InfA, ZIKV, DENV, NIPV/ ( ; ) | Imperial College London | Phase 1: ISRCTN17072692 | It is the purified synthetic mRNA which mimics the virus gene for a spike protein on its surface. |
4 | BNT162/ mRNA/ ( ; ; ) | BioNTech| FosunPharma| Pfizer | Phase 1 /2: NCT04380701 | A robust immunogenic response with the geometric mean of nAb titres to be 1.8 and 2.8 times the nAb titres in the convalescent serum panel after the administration of the second dose. |
4 | LNP-encapsulated mRNA cocktail encoding VLP/ RNA/ ( ; ) | Fudan University/ Shanghai JiaoTong University/RNA Cure Biopharma | Pre-Clinical | - |
5 | LNP-encapsulated mRNA cocktail encoding RBD/ mRNA/ ( ; ) | Fudan University/ Shanghai JiaoTong University/RNA Cure Biopharma | Pre-Clinical | - |
6 | mRNA onco-vaccine/ ( ) | BIOCAD | Pre-Clinical | They work by introducing sequences of molecules designed to make cells produce disease specific antigens and trigger a regular immune response. |
Protein Subunit Vaccine |
1 | VLP Recombinant Sub-unit, Full length S trimer/nanoparticle + Matrix M (NVX-CoV2373)/RSV, CCHF, HPV, VZV, EBOV/ ( ; ; ; ) | Novavax | Emergent BioSolutions | Phase 1: NCT04368988 | It demonstrated high immunogenicity in animal model with measuring anti spike antibodies, that prevent the attachment of the spike protein to the receptor, as well as wild-type virus neutralizing antibodies. |
2 | Molecular Clamp Stabilized Recombinant spike protein/Subunit/ Nipah, influenza, Ebola, Lassa/ ( ; ) | University of Queensland | GSK | Dynavax | Pre-Clinical | It is a stabilized pre-fusion viral protein sub-unit vaccine which is based upon the Molecular Clamp technology and uses AS03 adjuvant system from GSK. |
3 | S1 Microneedle array-based (PittCoVacc) Protein Subunit/ MERS/ ( ) ( ) | University of Pittsburgh | Pre-Clinical | Micro-needle Array-based delivery of the recombinant SARS-CoV-2 S1 induced a statistically significant antigen-specific antibody response within 2 weeks of administration in the mice models. |
4 | Recombinant protein Subunit vaccine/Influenza, SARS-CoV/ ( ) ( ) ( ) | Sanofi | Pre-Clinical | It is a recombinant vaccine of unrevealed SARS-CoV-2 protein(s) which is expressed in baculovirus vector system. |
5 | Protein Sub-unit, gp-96 based/ HIV, malaria, Zika/ ( ; ) | Heat Biologics | Program announced in March 2020 | It is a “Heat-shock protein gp96 complexed with an undisclosed SARS-CoV-2 peptide(s)”. This technology is capable of generating long-term immune responses and may confer immunity to different coronaviruses. |
| Virus Like Particle (VLP) vaccine/ ( ) | Medigaco | Pre-Clinical | A recombinant SARS-CoV-2 protein (undisclosed) VLP produced in tobacco. |
Live Attenuated Vaccine |
1 | Deoptimized live attenuated virus/ HAV, InfA, ZIKV, FMD, SIV, RSV, DENV / ( ; ) | Codagenix/Serum Institute of India | Pre-Clinical | Codagenix's technology allows for the rapid generation of multiple vaccine candidates against emerging viruses, starting with only the digital sequence of the viral genome. |
2 | TNX-1800, Live Attenuated Horsepox virus/ smallpox, monkeypox/ ( ) | Tonix Pharmaceuticals | Pre-IND | It is believed that horsepox has the potential to serve as a vector for vaccines to protect against other infectious agents. |
3 | Live attenuated recombinant measles virus (rMV)/ ( ; ; ) | ZydusCadila | Pre-Clinical | Codon-optimized proteins of the new coronavirus, expressed by rMV, will use reverse genetics to stimulate long-term neutralizing antibodies that protect against the infection |
Others |
1 | Self-assembling vaccine/ ( ) | HaloVax (Voltron Therapeutics) | The Vaccine & Immunotherapy Center at the Massachusetts General Hospital | Pre-Clinical (October 2020) | The biotinylated immunogenic fusion protein is sandwiched between heat shock protein and avidin. |
Legend: CCHF: Crimean-Congo Hemorrhagic Fever; CHIKV: Chikungunya Virus; DengV: Dengue Virus; FMD: Foot and Mouth Disease; EBOV: Ebola Virus; HAV: Hepatitis A Virus; HBV: Hepatitis B Virus; HIV: Human Immunodeficiency Virus; HPV: Human Papilloma Virus; Inf: Influenza; LASV: Lassa Fever Virus; MenB: Meningitis B; NIPV: Nipah Virus; NORV: Norovirus; RABV: Rabies Virus; RVF: Rift Valley Fever; SARS: Severe Acute Respiratory Syndrome; SIV: Simian Immunodeficiency Virus; TB: Tuberculosis; VEE: Venezuelan Equine; Encephalitis Virus; VZV: Varicella Vaccine (Chickenpox); YFV: Yellow Fever Virus; ZIKV: Zika Virus.
Latest developments in the status of the promising SARS-CoV-2 vaccines
Vaccine | Ref | Developer | Remarks | Clinical Trial Stage |
---|
ChAdOx1 | ( ) | University of Oxford/AstraZeneca | The preliminary reports of phase 1/2, single-blind, randomized controlled trials of the ChAdOx1 nCoV-19 vaccine have showcased the spike-specific T-cell responses along with the Anti-spike IgG response in 91% participants as per the micro-neutralization assay (MNA80) while a plaque reduction neutralization assay (PRNT50) depicted a 100% response after a single dose. Nevertheless, after the booster dose neutralizing response was seen in all the participants which had a substantial correlation with the neutralizing antibody titers as measured by ELISA. The volunteers depicted local and systemic reactions which were minimized by the administration of paracetamol. Thus, the vaccine candidate has portrayed adequate safety and immunogenicity profile in the phase 1/2 clinical trials. | Phase 3: ISRCTN89951424 |
mRNA-1273 | ( ) | Moderna/NIAID | The geometric mean of RBD specific antibody titers showed a rapid increase in all the participants. Seroconversion was observed after 15 days and the median magnitude of antibody responses was similar to the magnitude in convalescent sera. However, the pseudovirus neutralizing activity was not high before the administration of the second dose, which indicates the requirement of a two-dose vaccination schedule. Furthermore, the serum neutralizing activity, a generally accepted functional biomarker of the in vivo humoral response against the respiratory viruses, has not been determined as of now. | Phase 3: NCT04470427 |
PiCoVacc | ( ) | Sinovac | The phase 1/2 clinical trials of the inactivated viral vaccine candidate PiCoVacc demonstrated that the vaccine induces neutralizing antibodies with a seroconversion rate of 90% in a 0,14 day schedule. The preliminary results confirmed the absence of adverse systemic or local events post-vaccination. The phase 2 clinical trials are expected to be concluded by the end of 2020. The Company has got the permission for conducting the phase 3 clinical trials in Brazil in collaboration with Instituto Butantan. Furthermore, it is expected to get further approvals in Bangladesh for the phase 3 clinical trials. | Phase 3: NCT04456595 |
BBV152 (A-C) | ( ) | Bharat Biotech/ ICMR/ NIV | It is the whole virion inactivated experimental vaccine under the phase 1/2 clinical trials. These trials are supposed to study the safety and reactogenicity, tolerability, and the immunogenicity in the healthy volunteers. The inactivated vaccine shall be administered intramuscularly in two doses at day 0 and day 14 and the 1125 volunteers shall be observed for the next six months and will be evaluated for post-vaccination immune responses. The viral strain for the vaccine development was isolated by ICMR and transferred to Bharat Biotech where the process of inactivation was executed in a BSL-3 facility. | Phase 1/2: NCT04471519 |
Adenovirus Type5 Vector/ Non-replicating viral vaccine | ( ) | CanSino Biological Inc./Beijing Institute of Bio-technology | The randomized, double-blind, placebo controlled phase 2 clinical trials of the recombinant Ad5-vectored vaccine represented a positive cellular response at 5 × 10 viral particles along with seroconversion of the humoral immune response. Severe adverse reactions were reported in 9% of the individuals in the 1 × 10 viral particles dose group and 1% volunteers exhibited these adverse reactions in the 5 × 10 viral particles dose group. | Phase 2: ChiCTR2000031781 |
BNT162 | ( ) | BioNTech| FosunPharma| Pfizer | BNT162b1, the mRNA based vaccine induced a high, dose-dependent nAb titers along with the RBD-binding IgG concentrations after the second dose. This was accompanied by the CD4+ and CD8+ T cell responses. The administration of the vaccine was accompanied by certain adverse symptoms like fatigue, fever, chills, muscle pains etc. However, the recipients did not showcase any severe symptoms. | Phase 3: NCT04368728 |
ZyCoV-D | ( , ; ) | Zydus Cadila | ZyCoV-D is a genetically engineered DNA plasmid based vaccine encoding for the membrane proteins of the virus. The clinical trials to study the immunogenicity, and safety of the vaccine, will administer three doses at an interval of 28 days in 1048 individuals. | Phase 1/2: CTRI/2020/07/026352 |
3. Passive Immunization/adoptive immunity
It is the use of preformed antibodies in therapeutics of various diseases. It can be achieved by use of sera from convalescent patients, polyclonal serum raised in other animals such as horse, neutralizing monoclonal antibodies produced by hybridoma technology or humanized antibodies.
3.1. Convalescent Plasma therapy
To date, no distinct treatment has been proven to be efficacious against the COVID-19. Convalescent plasma (CP) therapy has been approved as an empirical treatment during the outbreaks ( (WHO), World Health Organisation, 2014 ). It is considered as the archetypal immunotherapy which has been used for the treatment and prevention of various viral diseases in the past such as SARS, MERS, H1N1 pandemic, measles, mumps, etc. ( Kai et al., 2020 ). A possible explanation for the efficacy of this classic adoptive immunotherapy is that the neutralizing immune-globulins from CP may conquer viremia, block new infection, and accelerate clearance of the infected cells.
Various studies conducted to evaluate therapeutic potential of CP have convincingly shown that administration of the neutralizing antibodies in the critically ill patients led to the amelioration of the clinical status in all patients without any deaths ( Kai et al., 2020 ; Shen et al., 2020a ; Ahn et al., 2020a ; Anon, 2020C ). The dosage prescribed for the CP therapy has not been standardized yet and needs Randomised Clinical Trials not only to eliminate the effect of other medicines but also to evaluate the efficacy and safety of CP therapy. ( Zhang et al., 2020 ). The patients who were considered critically ill with some of them having co-morbid conditions like hypertension, cardiovascular diseases, cerebrovascular diseases, chronic renal failure, etc. were included in the study. They were all admitted to the ICUs and were receiving either mechanical ventilation, high-flow nasal cannula oxygenation, or the low-flow nasal cannula oxygenation. All the patients in these studies were receiving antiviral or antibacterial or antifungal drugs for the treatment of co-infections ( Kai et al., 2020 ). Compared to the control group, the CP treatment group showed no notable differences in the baseline characteristics but exhibited a sizable difference in the clinical outcomes (i.e. normalization of the body temperature, absorption of pulmonary lesions, resolution of ARDS, weaning off the mechanical ventilators, etc.), and the death rates. The patients were tested negative for the viral loads after 7-37 days of CP infusion ( Shen et al., 2020b ). A reduction in the net quantity of inflammatory biomarkers CRP, procalcitonin, and Interleukin 6 (IL-6) in the trial group was observed along with a significant increase in the antibody titers (RBD specific IgM and IgG) post-convalescent plasma therapy ( Ahn et al., 2020b ). However, these uncontrolled and non-randomized trials for the CP therapy impede the researchers to come to a conclusive statement about the prospective potency of this treatment, and these observations require further evaluation which is ongoing in the clinical trials ( Yan, 2020 ).
3.2. Monoclonal Antibody
The monoclonal antibodies (mAb) or therapeutic antibodies, created in the laboratory are the clones of a unique parent which can bind to a single epitope, that is, they have a monovalent affinity ( Gelboin et al., 1999 ). The use of mAb in the prevention and treatment of infectious diseases can overcome various drawbacks which are cognate with the convalescent plasma therapy in terms of specificity, safety, low risk of blood-borne infection, purity, and other factors. A wide array of monoclonal antibodies have already been developed which are implemented in the anti-tumor, anti-platelet, or antiviral therapy ( Breedveld, 2000 ).
A SARS-CoV specific human mAb CR3022 has been found to bind with the RBD of the S protein of SARS-CoV-2, stipulating it as a prospective therapeutic agent, which can either be used alone or in combination therapy for the management of COVID-19 ( Tian et al., 2020 ). To achieve higher efficiency of disease prevention and treatment, a combinatorial effect of monoclonal antibodies recognizing different epitopes of the viral surface can be considered for the neutralization of the virus as it may prove to be more effective and prevent the viral escape ( Tian et al., 2020 ).
There are over 61 patents which claim to have prepared the SARS-specific, MERS-specific, and the diagnostic antibodies. Another group of 38 patents claims to have developed the antibodies that target the host proteins like IL-6/IL-6R, TLR3, CD16, ITAM (immune-receptor tyrosine-based activation motif), DC-SIGN (dendritic cell-specific intercellular adhesion molecule-grabbing non-integrin), ICAM-3 (intercellular adhesion molecule 3), or IP-10/CXCL10 (interferon γ-inducible protein 10). These antibodies can be used to counteract against the cytokine storm that has been reported to harmonize with the SARS-CoV-2 infection ( Liu et al., 2020 ). Tocilizumab, an anti-IL 6 receptor antibody is likely to control the hyper-inflammatory pulmonary symptoms which are coupled with the cytokine storm involving the chemokine dysregulation and various interleukins. Tocilizumab has been reported to block the cytokine axis IL6 hence inhibiting the inflammatory cascade. However, further clinical trials are essential to establish the effectiveness of the mAb ( Michot et al., 2020 ). Israel Institute for Biological Research (IIBR) claims to have successfully developed the mAb against SARS-CoV-2. The institute is in the process of patenting it which may soon be commercialized ( Upadhyay, 2020 ). A group led by Professor Vijay Chaudhary at the University of Delhi, Centre for Innovation in Infectious Disease Research, Education and Training (UDSC-CIIDRET), is isolating the genes encoding the antibodies responsible for the neutralization of the SARS-CoV-2. These genes will be employed to foster the recombinant Ab by exploiting the pre-existing in-house antibody library and a library fabricated from the cells of convalescent COVID-19 patients ( PIB, Delhi, 2020 ).
4. Limitations
The duration of clinical trials poses a sizable amount of hindrance to swift vaccine development. According to the norms laid down by the US Food and Drug Administration (FDA), and WHO, a vaccine candidate has to pass through at least three phases of placebo-controlled clinical trials for the validation of its safety and efficacy, which can take years to complete. Considering the severity of the pandemic, which has forced a complete shut-down of the global economy, speedy vaccine development is necessary. Some authors suggest that the controlled human challenge studies may be conducted to suitably divert the Phase 3 testing, and allow the rapid licensure of the immunogenic vaccines. However, in the expanded field study participants will be monitored constantly to look for any long-term implications posed by the vaccine. Furthermore, the safety trials for the special groups including, children and pregnant women, and immuno-compromised patients can be conducted before the extension of the vaccination to these groups ( Eyal et al., 2020 ).
The testing and development of safe and effective vaccines rely upon laboratory animal models. These animal models must show a similar course of the disease as in human beings. However, the standard inbred strains of mice are not susceptible to the COVID-19 infection, due to the difference between the humans and mice ACE2 receptors ( Anon, 2020D ). This calls for the development of transgenic mice, expressing the hACE2 receptor. Two animal models (hACE2 transgenic mice model and another, primate Macaques model) were previously developed for the SARS-CoV but the current situation requires steady breeding and distribution of these animal models to meet demands of the researchers around the globe ( Mice and Bao, 2020 ). The SARS-CoV-2 virus isolates can efficiently replicate in the lungs of the Syrian hamsters. The lungs of infected hamsters exhibit the pathological lesions analogous to the COVID-19 patients with pneumonia. Moreover, the nAb response exhibited by the infected hamster demonstrated immunity against the succeeding re-challenge studies. Furthermore, the transfusion of convalescent sera into the naïve hamsters mounted the antibody response and hence hindered the viral replication in the lungs. The assemblage of these experiments have illustrated the Syrian hamster may be a perfect model for comprehending SARS-CoV-2 pathogenesis, and evaluating antiviral drugs, and the immunotherapies ( Imai and Iwatsuki-Horimoto, 2020 ). Nevertheless, the assessment of the vaccine dependent immune enhancement cannot be extrapolated from the animal models and requires a legitimate survey from stage III human trials or the human challenge studies.
The Antibody dependent enhancement (ADE) is exploited by various viruses like Dengue, HIV, animal coronaviruses, etc. as an alternative method of infecting a variety of host cells. The virus-antibody complex can bind to the Fc receptors, activate the complement system, or induce a conformational change in the glycoprotein of the viral envelope ( Yip et al., 2016 ). This mechanism is observed when the vaccine-induced antibodies are either non-neutralizing or they are present in inadequate concentrations. This process triggers the viral entry into the cell due to the intensified binding efficiency of the virus-antibody complexes to FcR bearing cells. The clinical and preclinical trials of SARS-CoV vaccine candidates have demonstrated the aggravation of the disease due to ADE. Vaccine Associated Enhanced Respiratory Disease (VAERD) can also be induced by virus-antibody immune complex and T H 2-biased responses ( Graham, 2020 ).
The viral genome is vulnerable to mutations and can undergo the antigenic shift and the antigenic drift, as it continues to spread from one population to the next. The mutations may vary according to the environmental conditions of a geographical area, and the population density. By screening the 7500 samples of the infected patients, the scientists were able to figure out 198 mutations that may have materialized independently which may indicate the evolution of the virus inside the human host. These mutations may lead to different subtypes which may allow the virus to escape the immune system even after the administration of the vaccine ( Dorp et al., 2020 ).
5. Conclusion
SARS-CoV-2 has been the matter of the moment from the date it was declared as a pandemic, it has led to the termination of economic activities universally. Scientists across the continents are joining hands for the innovative tie-ups with both the pharmaceutical giants and the medical start-ups to repurpose drugs, develop vaccines, and devices to impede the progress of this overwhelming pandemic. A large number of COVID-19 vaccine candidates based upon various platforms have already been identified. Despite the undergoing efforts, a definitive answer does not exist. The process of vaccine development is quite laborious with various stages, including the pre-clinical stage, and clinical development which is a three-phase process. However, if sufficient data is already available, it has been recommended to skip a few stages, to accelerate the attainment of a vaccine faster with a quick regulatory review, approval, manufacturing, and quality control. This novel Coronavirus has therefore forced the scientific community to use unconventional approaches to accelerate the process of vaccine development. According to WHO: “vaccine must provide a highly favorable benefit-risk contour; with high efficacy, only mild or transient adverse effects and no serious ailments.” The vaccine must be suitable for all ages, pregnant, and lactating women and should provide a rapid onset of protection with a single dose and confer safety for at least up to one year of administration.
The use of novel technologies for vaccine development requires extensive testing for the safety and efficacy of a vaccine. The scientific community needs to construct various processes and capacities for the largescale manufacturing and administration of the coronavirus vaccines. The Coalition for Epidemic Preparedness Innovation (CEPI), an international non-governmental organization, which is funded by the Wellcome Trust, the European Commission, the Bill and Melinda Gates Foundation, and eight countries, is subsidizing the development of a large number of pandemic vaccine candidates around the globe. Moderna and the Vaccine Research Centre are co-developing an mRNA based vaccine candidate, wherein the mRNA is encapsulated in the lipid nanoparticles while Codagenix in collaboration with the Serum Institute of India is currently focused on developing the live attenuated viral vaccine. The pharmaceutical giants like Novavax, Sichuan Clover Biopharmaceuticals, iBio, and the University of Queensland are in the preclinical stage of the recombinant S glycoprotein vaccines. Additional strategies like the viral vector-based vaccines, targeting the S glycoprotein are being developed by the University of Oxford and CanSino Biologics, and other companies, Inovio and the Applied DNA Sciences are currently developing the DNA based vaccine candidates against the SARS-CoV-2 S Protein. Some of these vaccine candidates are at least months, away from being ready for human use, while others may take longer if at all approved for final use.
In India alone, six biotech ventures i.e. Serum Institute of India, ZydusCadila, Biological E, Indian Immunologicals, Bharat Biotech, and Mynvax are working in collaboration with various international vaccine developers. They are working on DNA vaccines, live attenuated recombinant measles vaccines, inactivated viral vaccines, subunit vaccines, and the vaccines developed by codon-optimization ( Coronavirus, 2020 ). Furthermore, the academic institutes like National Institute of Immunology (NII), Indian Institute of Science (IISc), International Center for Genetic Engineering and Biotechnology (ICGEB) New Delhi, Translational Health Science and Technology Institute (THSTI), etc. are attempting to develop the vaccines, and therapies, and the SARS-CoV-2 animal models to restrain the pandemic shortly ( Nandi, 2020 ).
The need of the hour is to develop a safe and effective COVID-19 vaccine which can induce an appropriate immune response to terminate this pandemic. It is the universal priority to spot the international funding mechanisms to support the development, manufacturing, and stockpiling of the coronavirus vaccines. This pandemic should serve as the guidepost to the international research community to not only acknowledge the outbreak but also indurate the following coronavirus crossing into mammals. A pan-coronavirus vaccine is urgently needed as the delay of vaccine rollout even by one week will accompany millions of deaths. Furthermore, it appears to be a scientifically feasible task if sufficient resources are made available in due time.
Funding Information
This work received no specific grant from any funding agency.
Declaration of Competing Interest
The author(s) declare that there are no conflicts of interest.
- Ahn J.Y., Sohn Y., Lee S.H., Cho Y., Hyun J.H., Baek Y.J., Jeong S.J., Kim J.H., Ku N.S., Yeom J.S., Roh J., Ahn M.Y., Chin B.S., Kim Y.S., Lee H., Yong D., Kim H.O., Kim S., Choi J.Y. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. J Korean Med Sci. 2020; 35 (14, April) doi: 10.3346/jkms.2020.35.e149. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Ahn J.Y., Sohn Y., Lee S.H., et al. Use of convalescent plasma therapy in two covid‐19 patients with acute respiratory distress syndrome in Korea. J Korean Med Sci. 2020 doi: 10.3346/jkms.2020.35.e149. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Anon . 2020. Countries where COVID-19 has spread. www.worldometers.info. [Online] July 30, 2020. [Cited: July 31, 2020.] https://www.worldometers.info/coronavirus/countries-where-coronavirus-has-spread/ . [ Google Scholar ]
- Anon . 2020. Coronavirus Resource Center. https://coronavirus.jhu.edu/. [Online] Johns Hopkins University. [Cited: August 05, 2020.] https://coronavirus.jhu.edu/map.html . [ Google Scholar ]
- Anon . 2020. COVID-19 Treatment and Vaccine Tracker. https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viweyymxOAtNvo7yH?blocks=bipZFzhJ7wHPv7x9z https://airtable.com/. [Online] Milken Institute. [ Google Scholar ]
- Anon . 2020. A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells) Registration no.: ChiCTR2000031809. http://www.chictr.org.cn/showprojen.aspx?proj=52227 http://www.chictr.org.cn. [Online] [ Google Scholar ]
- Anon . 2020. UW–Madison, FluGen, Bharat Biotech to develop CoroFlu, a coronavirus vaccine. https://www.businesswire.com/news/home/20200402005666/en/UW%E2%80%93Madison-FluGen-Bharat-Biotech-develop-CoroFlu-coronavirus https://www.businesswire.com. [Online] April 02. [ Google Scholar ]
- Anon . 2020. A Study of a Candidate COVID-19 Vaccine (COV001)https://clinicaltrials.gov/ct2/show/ {"type":"clinical-trial","attrs":{"text":"NCT04324606","term_id":"NCT04324606"}} NCT04324606 ?term=vaccine&cond=covid-19&draw=2 https://clinicaltrials.gov. [Online]. [Cited: June 8, 2020.] [ Google Scholar ]
- Anon . 2020. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)https://clinicaltrials.gov/ct2/show/ {"type":"clinical-trial","attrs":{"text":"NCT04283461","term_id":"NCT04283461"}} NCT04283461 ?term=vaccine&cond=covid-19&draw=2 https://clinicaltrials.gov/. [Online] [ Google Scholar ]
- Anon . 2020. Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus. https://investors.modernatx.com/. [Online] Moderna, Inc., May 18, 2020. [Cited: June 15, 2020.] https://investors.modernatx.com/news-releases/news-release-details/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine. [ Google Scholar ]
- Anon . 2020. Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers.https://clinicaltrials.gov/ct2/show/ {"type":"clinical-trial","attrs":{"text":"NCT04336410","term_id":"NCT04336410"}} NCT04336410 ?term=inovio&cond=covid-19&draw=2&rank=1 https://clinicaltrials.gov/. [Online] 2020. 1. [ Google Scholar ]
- Anon . The University of Hong Kong; 2020. HKU joins global partnership to develop COVID-19 vaccine. https://fightcovid19.hku.hk/hku-state-key-laboratory-for-emerging-infectious-diseases-joins-global-effort-to-develop-covid-19-vaccine/ https://fightcovid19.hku.hk/. [Online], March 18, 2020. [ Google Scholar ]
- Anon . 2020. (BAT), British and American Tobacco Company. Potential COVID-19 vaccine – BAT in the news. https://www.bat.com/group/sites/UK__9D9KCY.nsf/vwPagesWebLive/DOBNHBWR https://www.bat.com/. [Online] 2020. [Cited: June 1, 2020.] [ Google Scholar ]
- Anon . 2020. Immunity and Safety of Covid-19 Synthetic Minigene Vaccine.https://clinicaltrials.gov/ct2/show/ {"type":"clinical-trial","attrs":{"text":"NCT04276896","term_id":"NCT04276896"}} NCT04276896 https://clinicaltrials.gov. [Online] [ Google Scholar ]
- Anon . 2020. Safety and Immunity of Covid-19 aAPC Vaccine.https://clinicaltrials.gov/ct2/show/ {"type":"clinical-trial","attrs":{"text":"NCT04299724","term_id":"NCT04299724"}} NCT04299724 https://clinicaltrials.gov/. [Online] [ Google Scholar ]
- Anon . 2020. Sinovac gets regulatory approval to assess Covid-19 vaccine. https://www.clinicaltrialsarena.com/news/sinovac-covid-19-vaccine-trial-approval/ https://www.clinicaltrialsarena.com. [Online] April 15. [ Google Scholar ]
- Anon . 2020. Sinovac reports positive data from Phase I/II trials of CoronaVac. https://www.clinicaltrialsarena.com/news/sinovac-coronavac-data/ https://www.clinicaltrialsarena.com/. [Online] June 15, 2020. [Cited: June 20, 2020.] [ Google Scholar ]
- Anon . 2020. An Open Study of the Safety, Tolerability and Immunogenicity of the Drug "Gam-COVID-Vac" Vaccine Against COVID-19.https://clinicaltrials.gov/ct2/show/ {"type":"clinical-trial","attrs":{"text":"NCT04436471","term_id":"NCT04436471"}} NCT04436471 ?term=vaccine&cond=covid-19&draw=4 https://clinicaltrials.gov/. [Online] June 22, 2020. [Cited: June 22, 2020.]. NCT04436471. [ Google Scholar ]
- Anon . 2020. An Open Study of the Safety, Tolerability and Immunogenicity of "Gam-COVID-Vac Lyo" Vaccine Against COVID-19.https://clinicaltrials.gov/ct2/show/ {"type":"clinical-trial","attrs":{"text":"NCT04437875","term_id":"NCT04437875"}} NCT04437875 https://clinicaltrials.gov/. [Online] June 22, 2020. [Cited: June 22, 2020.]. NCT04437875. [ Google Scholar ]
- Anon . 2020. Vaxart Announces Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program. https://investors.vaxart.com/. [Online] Vaxart Inc., April 21, https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-positive-pre-clinical-data-its-oral-covid-19. [ Google Scholar ]
- Anon . 2020. Zydus Cadila looks to expedite Covid-19 vaccine development. https://www.pharmaceutical-technology.com/news/zydus-cadila-covid-19-vaccine/ https://www.pharmaceutical-technology.com. [Online] 17 February, [ Google Scholar ]
- Anon . 2020. Draft landscape of COVID-19 candidate vaccines. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines https://www.who.int/. [Online] June 22, 2020. [Cited: June 23, 2020.] [ Google Scholar ]
- Anon . 2020. Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women. http://www.isrctn.com/ISRCTN17072692 http://www.isrctn.com/ [Online] June 17, 2020. [Cited: June 22, 2020.]. ISRCTN17072692. [ Google Scholar ]
- Anon . 2020. A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults.https://clinicaltrials.gov/ct2/show/ {"type":"clinical-trial","attrs":{"text":"NCT04380701","term_id":"NCT04380701"}} NCT04380701 https://clinicaltrials.gov/. [Online] May 8. [ Google Scholar ]
- Anon . BIOCAD Biotechnology Company; 2020. BIOCAD started working on mRNA vaccine against coronavirus. https://biocadglobal.com/index.php?posts&post=45 https://biocadglobal.com/. [Online], March 19. [ Google Scholar ]
- Anon . 2020. Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS (COVID-19) Nanoparticle Vaccine With/Without Matrix-M Adjuvant.https://clinicaltrials.gov/ct2/show/record/ {"type":"clinical-trial","attrs":{"text":"NCT04368988","term_id":"NCT04368988"}} NCT04368988 https://clinicaltrials.gov/. [Online] May 27, 2020. [Cited: June 15, 2020.] [ Google Scholar ]
- Anon . 2020. Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine. http://www.news.sanofi.us/2020-02-18-Sanofi-joins-forces-with-U-S-Department-of-Health-and-Human-Services-to-advance-a-novel-coronavirus-vaccine http://www.news.sanofi.us/. [Online] Sanofi U.S., February 18, 2020. [ Google Scholar ]
- Anon . Medigaco Inc.; 2020. COVID-19 Vaccine Development Program. https://www.medicago.com/en/covid-19-programs/ https://www.medicago.com/. [Online] [ Google Scholar ]
- 2020. A randomized, double-blind, placebo parallel-controlled phase I/II clinical trial for inactivated Novel Coronavirus Pneumonia vaccine (Vero cells) http://www.chictr.org.cn/showprojen.aspx?proj=52227 http://www.chictr.org.cn. [Online] [ Google Scholar ]
- Anon . Sinovac Biotech Limited; 2020. Sinovac COVID-19 Vaccine Collaboration with Butantan Receives Approval from Brazilian Regulator for Phase III Trial. http://www.sinovac.com/?optionid=754&auto_id=907 http://www.sinovac.com/. [Online]July 06, 2020. [Cited: August 01, 2020.] [ Google Scholar ]
- Anon Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Chest. 2020;(March) doi: 10.1016/j.chest.2020.03.039. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Anon . 2020. COVID-19 / SARS-CoV-2. http://www.animalresearch.info/en/medical-advances/diseases-research/sars-cov-2/ http://www.animalresearch.info/. [Online] April 30, 2020. [Cited: June 11, 2020.] [ Google Scholar ]
- Arora Kajal, Rastogi Ruchir, et al. Multi-Antigenic Virus-like Particle of SARS CoV-2 produced in Saccharomyces cerevisiae as a vaccine candidate. Gurugram : s.n. bioRxiv. 2020;(May 19) doi: 10.1101/2020.05.18.099234. [ CrossRef ] [ Google Scholar ]
- Baruah V., Bose S. Immunoinformatics‐aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019‐nCoV. J Med Virol. 2020:495–500. doi: 10.1002/jmv.25698. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Breedveld F.C. Therapeutic monoclonal antibodies. The Lancet. 2000:735–740. doi: 10.1016/S0140-6736(00)01034-5. PMID 10703815. [ PubMed ] [ CrossRef ] [ Google Scholar ]
- BROOK, STONY . 2020. Applied DNA Sciences Subsidiary, LineaRx, and Takis Biotech Collaborate for Development of a Linear DNA Vaccine Candidate Against Wuhan Coronavirus 2019-nCoV. https://adnas.com/coronoavirus-applied-dna-linearx-takis-biotech-vaccine/ https://adnas.com/. [Online] Applied DNA Sciences, February 07. [ Google Scholar ]
- Campbell Molly. 2020. Current Efforts in COVID-19 Vaccine Development. https://www.technologynetworks.com/biopharma/articles/current-efforts-in-covid-19-vaccine-development-332429 https://www.technologynetworks.com/. [Online] Technology Networks, March 23. [ Google Scholar ]
- Cao Y., Zhu X., Hossen M.N., et al. Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant. Nat Commun. 2018 [ PMC free article ] [ PubMed ] [ Google Scholar ]
- Carter John, Saunders Venitia. Wiley; Hoboken, New Jersey: 2007. Virology: Principles and Applications; p. 382. ISBN: (Paperback) 9780470023877 [ Google Scholar ]
- (CDC), Centers for Disease Control and Prevention . CDC; 2020. How COVID-19 Spreads. [Online] 2020. [Cited: June 1, 2020.] https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/how-covid-spreads.html? CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fprepare%2Ftransmission.html. [ Google Scholar ]
- CDC Coronavirus Disease 2019 (COVID-19)- Symptoms of Covid-19. Centres for Disease Control and Prevention. 2020 https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html [Online]. [ Google Scholar ]
- Coleman Christopher M., Liu Ye V., Mu Haiyan, Taylor Justin K., Massare Michael, Flyer David C., Glenn Gregory M., Smith Gale E., Frieman Matthew B. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 2020:3169–3174. doi: 10.1016/j.vaccine.2014.04.016. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Conserved Protein Domain Family: SARS-like-CoV_M . 2020. NCBI. https://www.ncbi.nlm.nih.gov/Structure/cdd/cd21569 [Online]. [Cited: June 1, 2020.] [ Google Scholar ]
- Coronavirus . 2020. Around 30 Indian attempts at COVID-19 vaccine, says Principal Scientific Adviser. https://www.thehindu.com/ [Online] The Hindu, May 11, 2020. [Cited: June 11, 2020.] thehindu.com/sci-tech/health/coronavirus-around-30-indian-attempts-at-covid-19-vaccine-says-principal-scientific-adviser/article31560932.ece. [ Google Scholar ]
- CTRI/2020/07/026352. 2020 http://ctri.nic.in/. [Online] July 31, 2020. [Cited: August 01, 2020.] http://ctri.nic.in/Clinicaltrials/showallp.php?mid1=45306&EncHid=&userName=Zydus.
- Cuiling Zhang, Giulietta Maruggi, Hu Shan, Junwei Li. Advances in mRNA Vaccines for Infectious Diseases. Frontiers in Immunology. 2020:594. DOI=10.3389/fimmu.2019.00594. [ PMC free article ] [ PubMed ] [ Google Scholar ]
- da Silva S., da Silva C., Mendes R., Pena L. Role of Nonstructural Proteins in the Pathogenesis of SARS-CoV-2. Journal of medical virology. 2020 doi: 10.1002/jmv.25858. 10.1002/jmv.25858 p. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Delamater P.L., Street E.J., Leslie T.F., Yang Y., Jacobsen K.H. Complexity of the Basic Reproduction Number (R0) s.l. : Emerging Infectious Diseases. 2019; 25 doi: 10.3201/eid2501.171901. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Dhama K., Sharun K., Tiwari R., Dadar M., Malik Y.S., Singh K.P., Chaicumpa W. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020 doi: 10.1080/21645515.2020.1735227. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Doremalen Neeltje van, Lambe Teresa, Spencer Alexandra, Belij-Rammerstorfer Sandra, Purushotham Jyothi N., Port Julia R., Avanzato Victoria, Bushmaker Trenton, Flaxman Amy, Ulaszewska Marta, Feldmann Friederike, Allen Elizabeth R., Sharpe Hannah. Jonathan ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. s.l. : bioRxiv. 2020 doi: 10.1101/2020.05.13.093195. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Dorp Lucy van, Acman Mislav, Richard Damien, Shaw Liam P., Ford Charlotte E., Ormond Louise, Owen Christopher J., Pang Juanita, Tan Cedric C.S., Boshier Florencia A.T., Ortiz Arturo Torres, Balloux François. Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. s.l. : Infection, Genetics and Evolution. 2020; 104351 doi: 10.1016/j.meegid.2020.104351. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Eyal N., Lipsitch M., Smith P.G. Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. s.l. : The Journal of infectious diseases. 2020:1752–1756. doi: 10.1093/infdis/jiaa152. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Folegatti Pedro M, Ewer Katie J, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. The Lancet. 2020;(July) [ PMC free article ] [ PubMed ] [ Google Scholar ]
- Garg P., Srivastava N., Srivastava P. An Integrated In-Silico Approach to Develop Epitope-Based Peptide Vaccine against SARS-CoV-2. s.l. : Preprints. 2020 doi: 10.20944/preprints202005.0401.v1). [ CrossRef ] [ Google Scholar ]
- Gelboin Harry V, et al. Inhibitory monoclonal antibodies to human cytochrome P450 enzymes: a new avenue for drug discovery. Trends in Pharmacological Sciences. 1999:432–438. doi: 10.1016/S01. [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Gralinski L.E., Menachery V.D. Return of the Coronavirus: 2019-nCoV. Viruses. 2020:135. [ PMC free article ] [ PubMed ] [ Google Scholar ]
- Graham B.S. Rapid COVID-19 vaccine development. Science. 2020;(May 29):945–946. [ PubMed ] [ Google Scholar ]
- Gupta V., Tabiin T.M., Sun K., Chandrashekaran A., Anwar A., Yang K., Chikhlikar P., Salmon J., Brusic V., Marques E.T.A., Kellathur S.N., August T.J. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens. Virology. 2006; 347 (1):127–139. (impact factor: 2.657) [ PMC free article ] [ PubMed ] [ Google Scholar ]
- Heat Biologics’ COVID-19 Vaccine Program . 2020. Heat Biologics. https://www.heatbio.com/product-pipeline/covid-19-vaccine https://www.heatbio.com/. [Online] [ Google Scholar ]
- Hobernik D., Bros M. DNA Vaccines-How Far From Clinical Use? Int J Mol Sci. 2018:3605. doi: 10.3390/ijms19113605. PMID: 30445702; PMCID: PMC6274812. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Hoffmann Markus, Kleine-Weber Hannah, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020:271–280. doi: 10.1016/j.cell.2020.02.052. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Imai Masaki, Iwatsuki-Horimoto Kiyoko, et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proceedings of the National Academy of Sciences. 2020;(May):16587–16595. [ PMC free article ] [ PubMed ] [ Google Scholar ]
- Jackson Lisa A., Anderson, Evan J., et al. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med. 2020;(July) [ PMC free article ] [ PubMed ] [ Google Scholar ]
- Jiang S., Du L., Shi Z. An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerging microbes & infections. 2020:275–277. doi: 10.1080/22221751.2020.1. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19 . 2020. Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use. https://www.prnewswire.com/news-releases/johnson--johnson-announces-a-lead-vaccine-candidate-for-covid-19-landmark-new-partnership-with-us-department-of-health--human-services-and-commitment-to-supply-one-billion-vaccines-worldwide-for-emergency-pandemic- https://www.prnewswire.com/. [Online] [ Google Scholar ]
- Kai Duan, Liu Bende, Li Cesheng, Zhang Huajun, Yu Ting, Qu Jieming, Zhou Min, Chen Li, Meng Shengli, Hu Yong, Peng Cheng, Yuan Mingchao, Huang Jinyan, Wang Zejun, Yu Jianhong, Gao Xiaoxiao, Wang Dan, Yu Xiaoqi, Li Li., Zhang Jiayou, Wu Xiao, Li Bei, Yanpin Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020;(April) doi: 10.1073/pnas.2004168117. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Kim E., et al. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development. EBioMedicine. 2020 doi: 10.1016/j.ebiom.2020.102743. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Lauer S.A., Grantz K.H., Bi Q., et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med. 2020:577–582. [ PMC free article ] [ PubMed ] [ Google Scholar ]
- Le Tung Thanh, Andreadakis Zacharias, Kumar Arun, Román Raúl Gómez, Tollefsen Stig, Saville Melanie, Mayhew Stephen. The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery. 2020; 19 (5):305–306. [ PubMed ] [ Google Scholar ]
- Lee Jaimy. These 23 companies are working on coronavirus treatments or vaccines — here’s where things stand. Market watch. 2020 https://www.marketwatch.com/story/these-nine-companies-are-working-on-coronavirus-treatments-or-vaccines-heres-where-things-stand-2020-03-06 [Online] May 6, 2020. [Cited: June 1, 2020.] [ Google Scholar ]
- Liu Cynthia, Zhou Qiongqiong, Li Yingzhu, Garner Linda V., Watkins Steve P., Carter Linda J., Smoot Jeffrey, Gregg Anne C., Daniels Angela D., Jervey Susan, Albaiu Dana. Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases. ACS Central Science. 2020:315–331. doi: 10.1021/acscentsci.0c00272. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Masihi K Noel. Fighting infection using immunomodulatory agents. Expert Opinion on Biological Therapy. 2001:641–653. doi: 10.1517/14712598.1.4.641. [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Mice L., Bao, et al. The Pathogenicity of 2019 Novel Coronavirus in hACE2 Transgenic. s.l. : bioRxiv. 2020 doi: 10.1101/2020.02.07.939389. preprint. [ CrossRef ] [ Google Scholar ]
- Michot Jean-Marie, Albiges Laurence, Chaput Nathalie, Saada Veronique, Fanny Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Annals of Oncology. 2020 doi: 10.1016/j.annonc.2020.03.300. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Mulligan Mark J., Lyke Kirsten E., et al. Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report; preprint. s.l. : medRxiv. 2020 06.30.20142570, 2020, medRxiv. [ Google Scholar ]
- Myupchar . 2020. Race for COVID-19 vaccine: Covaxin and ZyCoV-D begin human trials in India, Moderna publishes preliminary data from phase 1. https://www.firstpost.com/health/race-for-covid-19-vaccine-covaxin-and-zycov-d-begin-human-trials-in-india-moderna-publishes-preliminary-data-from-phase-1-8600211.html/amp https://www.firstpost.com/. [Online] July 15, 2020. [Cited: August 01, 2020.] [ Google Scholar ]
- Nandi Jayashree. 2020. Top Indian scientists join global fight against coronavirus. https://www.hindustantimes.com/india-news/top-indian-scientists-join-global-fight-against-virus/story-CKRGfycsjBJD2ypLcbJPHM.html https://www.hindustantimes.com. [Online] Hindustan Times, New Delhi, March 30, 2020. [Cited: June 9, 2020.] [ Google Scholar ]
- Ning Wang, Jian Shang, Shibo Jiang, Lanying Du. Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. Frontiers in Microbiology. 2020 doi: 10.3389/fmicb.2020.00298. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Novavax covid 19 vaccine trial . 2020. Clinical Trials Arena. https://www.clinicaltrialsarena.com/news/novavax-covid-19-vaccine-trial/ [Online] [ Google Scholar ]
- Ou X., Liu Y., Lei X., et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020; 1620 :11. doi: 10.1038/s41467-020-15562-9. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Park Su Eun. Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19) Clin Exp Pediatr. 2020:119–124. doi: 10.3345/cep.2020.00493. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Pharmaceutical Targeting the Envelope Protein of SARS-CoV-2: the Screening for Inhibitors in Approved Drugs . XR Pharmaceuticals Ltd.; Cambridge, New Zealand: 2020. Chernyshev, Anatoly. [ Google Scholar ]
- PIB, Delhi . 2020. DBT/ Anti-COVID consortium- Efforts underway to produce therapeutic antibodies against COVID-19: Isolating genes encoding antibodies for neutralising the SARS-CoV-2, COVID-19. https://pib.gov.in/. [Online] April 12, 2020. [Cited: June 07, 2020.] https://pib.gov.in/PressReleaseIframePage.aspx? PRID=1613531. [ Google Scholar ]
- Prof Roujian Lu, Zhao Xiang, Li Juan, Niu Peihua, Bo Yang, Honglong Wu, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. The Lancet. 2020:565–574. doi: 10.1016/S0140-6736(20)30251-8. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Pyrek Kelly M. 2018. 100 Years after the Spanish Flu: Lessons Learned and Challenges for the Future. https://www.infectioncontroltoday.com/ [Online] October 11, 2018. https://www.infectioncontroltoday.com/public-health/100-years-after-spanish-flu-lessons-learned-and-challenges-future. [ Google Scholar ]
- Shang W., Yang Y., Rao Y., et al. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines. NPJ Vaccines. 2020 doi: 10.1038/s41541-020-0170-0. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Shen Chenguang, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323 (16):1582–1589. doi: 10.1001/jama.2020.4783. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Shen C., Wang Z., Zhao F., et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323 (16):1582–1589. doi: 10.1001/jama.2020.4783. 2020. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Smith T.R.F., Patel A., Ramos S., et al. Immunogenicity of a DNA vaccine candidate for COVID-19. 2601. s.l. : Nat Commun. 2020; 11 doi: 10.1038/s41467-020-16505-0. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Tai W., He L., Zhang X., et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020 doi: 10.1038/s41. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- TNX-1800 (Coronavirus Vaccine) 2020. Online] Tonix Pharmaceuticals. https://www.tonixpharma.com/pipeline/tnx-1800-coronavirus-vaccine https://www.tonixpharma.com. [ Google Scholar ]
- Tian X., Li C., Huang A., Xia S., Lu S., Shi Z., Lu L., Jiang S., Yang Z., Wu Y., Ying T. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific. Emerg Microbes Infect. 2020:382–385. doi: 10.1080/22221751.2020.1729069. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Tu Y.-F., Chien C.-S., Yarmishyn A.A., Lin Y.-Y., Luo Y.-H., Lin Y.-Y., Lai W.-Y., Yang D.-M., Chou S.-J., Yang Y.-P., Wang M.-L., Chiou S.-H. A Review of SARS-CoV-2 and the Ongoing Clinical Trials. International Journal of Molecular Sciences. 2020:2657. [ PMC free article ] [ PubMed ] [ Google Scholar ]
- Upadhyay Lipi. 2020. Italy claims to have developed the first COVID-19 vaccine: Here is what we know about all the potential coronavirus vaccines. https://timesofindia.indiatimes.com/life-style/health-fitness/health-news/italy-claims-to-develop-first-covid-19-vaccine-here-is-the-current-status-of-all-the-potential-coronavirus-vaccines/photostory/75575319.cms https://timesofindia.indiatimes.com/. [Online] May 8, 2020. [Cited: May 31, 2020.] [ Google Scholar ]
- Ura T., Okuda K., Shimada M. Developments in Viral Vector-Based Vaccines. Vaccines (Basel) 2014:624–641. doi: 10.3390/vaccines2030624. PMID: 26344749; PMCID: PMC4494222. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Voltron Therapeutics, Inc . 2020. Enters into Sponsored Research Agreement with The Vaccine & Immunotherapy Center at the Massachusetts General Hospital to Develop Potential COVID-19 Vaccine. https://www.prnewswire.com/news-releases/voltron-therapeutics-inc-enters-into-sponsored-research-agreement-with-the-vaccine--immunotherapy-center-at-the-massachusetts-general-hospital-to-develop-potential-covid-19-vaccine-301034225.html https://www.prnewswire.com/. [Online] April 02, 2020. [ Google Scholar ]
- Walls A.C., Park Y.-J., Tortorici M.A., Wall A., McGuire A.T., Vessler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020:281–292. [ PMC free article ] [ PubMed ] [ Google Scholar ]
- Walls Structure, Function, and Antigenicity of the SARSCoV-2 Spike Glycoprotein. Cell. 2020:281–292. [ PMC free article ] [ PubMed ] [ Google Scholar ]
- Wan Y., Shang J., Graham R., Baric R.S., Li F. Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS. J Virol. 2020 doi: 10.1128/JVI.00127-20. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- (WHO), World Health Organisation . s.l. : World Health Organisation; 2014. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease. September [ Google Scholar ]
- (WHO) World Health Organisation . s.l.: World Health Organisation; 2020. Coronavirus disease (Covid-19) Situation Report- 164. [ Google Scholar ]
- WHO . s.l. : World Health Organisation; 2020. Draft landscape of COVID-19 candidate vaccines. [ Google Scholar ]
- Wrapp Daniel, Wang Nianshuang, Corbett Kizzmekia S., Goldsmith Jory A., Hsieh Ching-Lin, Abiona Olubukola, Graham Barney S., Jason S. Mclellan Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;(13 March):1260–1263. [ PMC free article ] [ PubMed ] [ Google Scholar ]
- Wu A., Peng Y., Huang B., Ding X., Wang X., Niu P., et al. Commentary genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020:325–328. doi: 10.1016/j.chom.2020.02.001. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020 [ PMC free article ] [ PubMed ] [ Google Scholar ]
- Yan, Xuebing. 2020 http://www.chictr.org.cn/showprojen.aspx?proj=49544. http://www.chictr.org.cn. [Online] February 2020.
- Yip M.S., Leung H.L., Li P.H., Cheung C.Y., Dutry I., Li D., Daëron M., Bruzzone R., Peiris J.S.M., Jaume M. Hong Kong Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS: s.n. Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine. 2016:25–31. [ PubMed ] [ Google Scholar ]
- Yoshimoto F.K. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The protein journal. 2020:198–216. doi: 10.1007/s10930-020-09901-4. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Zhai P., Ding Y., Wu X., Long J., Zhong Y., Li Y. The epidemiology, diagnosis and treatment of COVID-19. International Journal of Antimicrobial Agents. 2020 doi: 10.1016/j.ijantimicag.2020.105955. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Zhang B., Liu S., Tan T., et al. Treatment with convalescent plasma for critically ill patients with SARS‐CoV‐2 infection. Chest. 2020; 2020 :30571–30577. [ PMC free article ] [ PubMed ] [ Google Scholar ]
- Zhu Feng-Cai, Li Yu-Hua, Guan Xu-Hua, Hou Li-Hua, Wang Wen-Juan, Li Jing-Xin, Wu Shi-Po, Wang Bu-Sen, Wang Zhao, Wang Lei, Jia Si-Yue, Jiang Hu-Dachuan, Wang Ling, Jiang Tao, Hu Yi, Gou Jin-Bo, Xu Sha-Bei, Xu Jun-Jie, Wang Xue-Wen, Wang Wei, Chen Wei. Safety, tolerability, and immunogenicity of a recombinan tadenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet. 2020 doi: 10.1016/S0140-6736(20)31208-3. [ PMC free article ] [ PubMed ] [ CrossRef ] [ Google Scholar ]
- Zhu Feng-Cai, Guan Xu-Hua, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. 2020;(July) [ PMC free article ] [ PubMed ] [ Google Scholar ]
![](//cintadecorrer.fun/777/templates/cheerup1/res/banner1.gif)
COMMENTS
Our analyses indicate that vaccine effectiveness generally decreases over time against SARS-CoV-2 infections, hospitalisations, and mortality. The baseline vaccine effectiveness levels for the omicron variant were notably lower than for other variants. Therefore, other preventive measures (eg, face-mask wearing and physical distancing) might be necessary to manage the pandemic in the long term.
Introduction. The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in over 192 million cases and 4.1 million deaths as of July 22, 2021. 1 This pandemic has brought along a massive burden in morbidity and mortality in the healthcare systems. Despite the implementation of stringent public health measures, there ...
Safety and adverse effects of current COVID-19 vaccines. As shown in Table I, current vaccines have demonstrated considerable efficacy in diminishing mild, moderate and severe cases with a low risk of adverse events 21.For some of these vaccines [such as Convidicea (AD5-nCoV), Janssen (Ad26.COV2.S), Sinopharm (BBIBP-CorV), Covaxin (BBV152) and Sinovac (CoronaVac)], there is the information ...
Discussion. A two-dose regimen of BNT162b2 (30 μg per dose, given 21 days apart) was found to be safe and 95% effective against Covid-19. The vaccine met both primary efficacy end points, with ...
Although Covid-19 vaccines have been recommended for adults with chronic medical conditions, 22 ... The activity reported in this article was deemed not to be research as defined in 45 Code of ...
1. Safety and immunogenicity study of 2019-nCoV vaccine (mRNA-1273) for prophylaxis of SARS-CoV-2 infection (COVID-19) This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of mRNA-1273. It encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2.
The protective effects of vaccination and prior infection against severe Covid-19 are reviewed, with proposed directions for future research, including mucosal immunity and intermittent vaccine boo...
No vaccine was statistically significantly associated with a decreased risk for severe COVID-19 than other vaccines, although mRNA-1273 and Gam-COVID-Vac have the highest P-scores (0.899 and 0.816 ...
Our understanding of COVID-19 vaccinations and their impact on health and mortality has evolved substantially since the first vaccine rollouts. Published reports from the original randomized phase 3 trials concluded that the COVID-19 mRNA vaccines could greatly reduce COVID-19 symptoms. In the inter …
The persisting risk of long-term health consequences of SARS-CoV-2 infection and the protection against such risk conferred by COVID-19 vaccination remains unclear. Here we conducted a ...
The effectiveness of the mRNA vaccines in preventing COVID-19 disease progression in 2021 set new expectations about the role of prevention interventions for the disease. Efficacy observed in the trials was more than 90%.1,2 The efficacy of other vaccines evaluated in large randomised trials, such as the Oxford-AstraZeneca (70%) and Sputnik V (91%) vaccines, have been criticised for elements ...
While efficacious vaccines have been developed to inoculate against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; also known as COVID-19), public vaccine hesitancy could still ...
Authors' conclusions: Compared to placebo, most vaccines reduce, or likely reduce, the proportion of participants with confirmed symptomatic COVID-19, and for some, there is high-certainty evidence that they reduce severe or critical disease. There is probably little or no difference between most vaccines and placebo for serious adverse events.
2020 has been a difficult year for all, but has seen 58 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) be developed and in clinical trials,1 with some vaccines reportedly having more than 90% efficacy against COVID-19 in clinical trials. This remarkable achievement is much-needed good news as COVID-19 cases are currently at their highest daily levels globally.2 ...
To date, coronavirus disease 2019 (COVID-19) becomes increasingly fierce due to the emergence of variants. Rapid herd immunity through vaccination is needed to block the mutation and prevent the emergence of variants that can completely escape the immune surveillance. We aimed to systematically evaluate the effectiveness and safety of COVID-19 vaccines in the real world and to establish a ...
Community‐based studies in five countries show consistent strong benefits from early rollouts of COVID‐19 vaccines. By the beginning of June 2021, almost 11% of the world's population had received at least one dose of a coronavirus disease 2019 (COVID‐19) vaccine. 1 This represents an extraordinary scientific and logistic achievement ...
The Coronavirus Efficacy (COVE) phase 3 trial was launched in late July 2020 to assess the safety and efficacy of the mRNA-1273 vaccine in preventing SARS-CoV-2 infection. An independent data and ...
Introduction: In 2020, prior to COVID-19 vaccine rollout, the Brighton Collaboration created a priority list, endorsed by the World Health Organization, of potential adverse events relevant to COVID-19 vaccines. We adapted the Brighton Collaboration list to evaluate serious adverse events of special interest observed in mRNA COVID-19 vaccine trials.
The large number of COVID-19 vaccine induced deaths evaluated in this review is coherent with multiple papers that report excess mortality after COVID-19 vaccination. Pantazatos and Seligmann found that all-cause mortality increased 0-5 weeks post-injection in most age groups resulting in 146,000 to 187,000 vaccine-associated deaths in the ...
The effectiveness against infection of COVID-19 vaccines waned considerably 5-8 months after primary vaccination, although it remained high, particularly among people younger than 55 years. Vaccine boosters were effective in restoring protection against infection and had a good safety profile in the community.
There is no question that the current vaccines are effective and safe. The risk of severe reaction to a COVID-19 jab, say researchers, is outweighed by the protection it offers against the deadly ...
We characterized reports of myocarditis or pericarditis after COVID-19 vaccination that met the CDC's case definition and were received by VAERS between December 14, 2020 (when COVID-19 vaccines were first publicly available in the US), and August 31, 2021, by age, sex, race, ethnicity, and vaccine type; data were processed by VAERS as of ...
Abstract. The coronavirus disease 2019 (COVID-19) pandemic is a global crisis, with devastating health, business and social impacts. Vaccination is a safe, simple, and effective way of protecting a person against COVID-19. By the end of August 2021, only 24.6% of the world population has received two doses of a COVID-19 vaccine.
This study evaluates the effectiveness of the novel BNT162b2 mRNA vaccine 1 against Covid-19 in a nationwide mass vaccination setting. Estimated vaccine effectiveness during the follow-up period ...
John Ioannidis, a professor of medicine at the Stanford Prevention Research Center, said placing the burden of excess deaths on Covid-19 vaccines was "a long stretch"(archived here).
It is highlighted that Kikuchi-Fujimoto disease should be considered in the differential diagnosis of patients with axillary lymphadenopathy who have undergone COVID-19 vaccination, as unusual side effects of COVID -19 vaccination have been increasingly reported in the literature owing to the rapid development of various CO VID-19 vaccines during the pandemic period.
The coronavirus disease 2019 (COVID-19) has caused millions of deaths worldwide since the first reported suspected case in Wuhan, China, in late December 2019 1.Even though most patients will ...
Paper Context. Main findings: The research found that Bangladesh has achieved a world-standard surveillance system, with facilitating factors including multi-sectoral collaboration, GPEI partners, and political and community support. However, high population growth, hard-to-reach areas and people, and polio transition planning were found to be challenges.
2. Vaccination strategies. Many efforts have been directed towards the development of the vaccines against COVID-19, to avert the pandemic and most of the developing vaccine candidates have been using the S-protein of SARS-CoV-2 (Dhama et al., 2020).As of July 2, 2020, the worldwide SARS-CoV-2 vaccine landscape includes 158 vaccine candidates, out of which 135 are in the preclinical or the ...